ObesityWeek 2023
Highlights from ObesityWeek 2023, October 14 – 17.
Certain factors predict weight regain
Presenter: Suzanne Phelan, PhD, California Polytechnic State University, San Luis Obispo
Weight regain was common among long-term weight-loss maintainers and was associated with declines in regulating eating in response to food cues, in self-monitoring, and worsening body image.
Combined GLP-1 medication and virtual coaching leads to sustained weight loss
Presenter: Donna Ryan MD, Pennington Biomedical Research Center, Baton Rouge, LA
Combining glucagon-like peptide 1 (GLP-1) receptor agonist medications with intensive lifestyle interventions can lead to sustained weight loss, according to data from a real-world virtual obesity treatment program.
Type of insurance carrier plays a role in persistence with antiobesity medications
Presenter: Hamlet Gasoyan, PhD, Associate Staff, Cleveland Clinic
The type of an obese patient’s insurance may play a role in how long patients stay on antiobesity medications, according to a retrospective cohort study. Moreover, considerable disparities exist in whether patients receive antiobesity medications or GLP-1 receptor agonists at all, based on sociodemographic and insurance-related factors.
Weight regain after bariatric surgery does not increase long-term mortality
Presenter: Markku Peltonen, PhD, Professor, Finnish Institute for Health and Welfare, Chronic Disease Prevention Unit
Obese patients who regained more than 20% of their maximal weight loss within 4 years after bariatric surgery had a similar mortality rate compared with those who kept their weight off, according to an analysis of the Swedish Obesity Study.
Obese patients taking antidepressants lost weight on semaglutide
Presenter: Robert F. Kushner, MD, Professor, Departments of Medicine and Medical Education, Northwestern University Feinberg School
Obese patients taking antidepressants lost as much weight on semaglutide as those not on antidepressants in a post-hoc analysis of the Semaglutide Treatment Effect in People with Obesity (STEP) trials.
Tirzepatide adds significant weight loss even after lifestyle changes
Presenter: Ariana Chao, PhD, RN, Johns Hopkins University School of Nursing, Baltimore, MD
After losing at least 5% of body weight after 12 weeks of diet and exercise, patients who took the dual glucagon-like peptide 1 and gastric inhibitory polypeptide receptor agonist tirzepatide lost an additional 18.4% of weight, according to results from the phase 3 SURMOUNT-3 trial.